Effect of latanoprost as adjunctive therapy.

BACKGROUND: Latanoprost may be a useful adjunct in some patients receiving maximum tolerated medical therapy. We report our clinical experience with latanoprost when added to one or two other glaucoma medications. METHODS: Review of the charts of 53 patients with open-angle glaucoma whose intraocular pressure (IOP) was uncontrolled with one or two glaucoma medications and who had latanoprost added as a second or third drug. Patients whose IOP decreased by 3 mm Hg or more were considered to be responders. RESULTS: The shortest length of follow-up was 2.3 months (median 5.8 months). Latanoprost was given as a second medication to 35 patients, of whom 22 (63%) responded, with a mean IOP reduction of 6.1 mm Hg (standard deviation [SD] 2.73 mm Hg) (28.7% [SD 12.10%]). Of the 18 patients to whom latanoprost was given as a third medication, 10 (56%) responded, with a mean IOP reduction of 6.3 mm Hg (SD 3.86 mm Hg) (24.5% [SD 10.12%]). INTERPRETATION: Latanoprost provides additional IOP reduction in some patients with open-angle glaucoma when added to one or two other glaucoma medications.

Bilateral ptosis and lower eyelid ectropion secondary to cutaneous leishmaniasis.

A 73-year-old white woman had a 14-month history of an extensive, disfiguring facial lesion involving the cheeks, nose, and eyelids, resulting in exposure keratopathy. A biopsy of the facial lesion established the diagnosis of cutaneous leishmania, and the lesion responded to treatment with itraconazole.